Cargando…

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative approach for treating peritoneal carcinomatosis that applies chemotherapeutic drugs into the peritoneal cavity as an under-pressure airflow. It improves local bioavailability of cytostatic drugs as compared to conventional int...

Descripción completa

Detalles Bibliográficos
Autores principales: De Simone, Michele, Vaira, Marco, Argenziano, Monica, Berchialla, Paola, Pisacane, Alberto, Cinquegrana, Armando, Cavalli, Roberta, Borsano, Alice, Robella, Manuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277495/
https://www.ncbi.nlm.nih.gov/pubmed/32365877
http://dx.doi.org/10.3390/biomedicines8050102
_version_ 1783543131335032832
author De Simone, Michele
Vaira, Marco
Argenziano, Monica
Berchialla, Paola
Pisacane, Alberto
Cinquegrana, Armando
Cavalli, Roberta
Borsano, Alice
Robella, Manuela
author_facet De Simone, Michele
Vaira, Marco
Argenziano, Monica
Berchialla, Paola
Pisacane, Alberto
Cinquegrana, Armando
Cavalli, Roberta
Borsano, Alice
Robella, Manuela
author_sort De Simone, Michele
collection PubMed
description Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative approach for treating peritoneal carcinomatosis that applies chemotherapeutic drugs into the peritoneal cavity as an under-pressure airflow. It improves local bioavailability of cytostatic drugs as compared to conventional intraperitoneal chemotherapy. The aim of this study is to prove feasibility, efficacy and safety of this new treatment. Patients included in the analysis underwent at least two single port PIPAC procedures; drugs used were Oxaliplatin for colorectal cancers and Cisplatin + Doxorubicin for ovarian, gastric, and primary peritoneal cancers. The primary endpoint was the Disease Control Rate according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Secondary significant endpoints were overall and progression free survival, tumor regression on histology, and quality of life. Safety and tolerability were assessed according to the Common Terminology Criteria for Adverse Events 4. Sixty-three patients were enrolled in this trial. Forty patients (100 PIPAC) were eligible for analysis. Twenty patients were undergoing systemic chemotherapy. Fourteen patients reported an objective response (35%). Median overall survival was 18.1 months; median progression-free survival was 7.4 months. Minor morbidity was observed in seven procedures. Grade 3 complications occurred in two patients, and grade 4 in one patient submitted to reoperation. Single-port PIPAC is feasible, safe, and easy to perform. The combined treatment based on systemic chemotherapy and PIPAC does not induce significant hepatic and renal toxicity and can be considered a valid therapeutic option in patients with advanced peritoneal disease. Further studies on the use of PIPAC alone, possibly with different drug dosages, may define the real effectiveness of the procedure.
format Online
Article
Text
id pubmed-7277495
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72774952020-06-12 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial De Simone, Michele Vaira, Marco Argenziano, Monica Berchialla, Paola Pisacane, Alberto Cinquegrana, Armando Cavalli, Roberta Borsano, Alice Robella, Manuela Biomedicines Article Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative approach for treating peritoneal carcinomatosis that applies chemotherapeutic drugs into the peritoneal cavity as an under-pressure airflow. It improves local bioavailability of cytostatic drugs as compared to conventional intraperitoneal chemotherapy. The aim of this study is to prove feasibility, efficacy and safety of this new treatment. Patients included in the analysis underwent at least two single port PIPAC procedures; drugs used were Oxaliplatin for colorectal cancers and Cisplatin + Doxorubicin for ovarian, gastric, and primary peritoneal cancers. The primary endpoint was the Disease Control Rate according to the RECIST (Response Evaluation Criteria in Solid Tumors) criteria. Secondary significant endpoints were overall and progression free survival, tumor regression on histology, and quality of life. Safety and tolerability were assessed according to the Common Terminology Criteria for Adverse Events 4. Sixty-three patients were enrolled in this trial. Forty patients (100 PIPAC) were eligible for analysis. Twenty patients were undergoing systemic chemotherapy. Fourteen patients reported an objective response (35%). Median overall survival was 18.1 months; median progression-free survival was 7.4 months. Minor morbidity was observed in seven procedures. Grade 3 complications occurred in two patients, and grade 4 in one patient submitted to reoperation. Single-port PIPAC is feasible, safe, and easy to perform. The combined treatment based on systemic chemotherapy and PIPAC does not induce significant hepatic and renal toxicity and can be considered a valid therapeutic option in patients with advanced peritoneal disease. Further studies on the use of PIPAC alone, possibly with different drug dosages, may define the real effectiveness of the procedure. MDPI 2020-04-30 /pmc/articles/PMC7277495/ /pubmed/32365877 http://dx.doi.org/10.3390/biomedicines8050102 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Simone, Michele
Vaira, Marco
Argenziano, Monica
Berchialla, Paola
Pisacane, Alberto
Cinquegrana, Armando
Cavalli, Roberta
Borsano, Alice
Robella, Manuela
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
title Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
title_full Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
title_fullStr Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
title_full_unstemmed Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
title_short Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial
title_sort pressurized intraperitoneal aerosol chemotherapy (pipac) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase ii clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277495/
https://www.ncbi.nlm.nih.gov/pubmed/32365877
http://dx.doi.org/10.3390/biomedicines8050102
work_keys_str_mv AT desimonemichele pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT vairamarco pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT argenzianomonica pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT berchiallapaola pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT pisacanealberto pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT cinquegranaarmando pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT cavalliroberta pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT borsanoalice pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial
AT robellamanuela pressurizedintraperitonealaerosolchemotherapypipacwithoxaliplatincisplatinanddoxorubicininpatientswithperitonealcarcinomatosisanopenlabelsinglearmphaseiiclinicaltrial